Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 128 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Interferon-beta (IFN-beta) Clear all

Conditions: Multiple Sclerosis
Interventions: Avonex (Interferon beta 1a), Riluzole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif, Tecfidera; Drug
Lead sponsor: IMS HEALTH GmbH & Co. OHG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon beta-1b, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 33 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Many Locations, Alabama • Many Locations, Arizona • Many Locations, California + 3 more

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Interventions: VV1, Cemiplimab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Early Highly Effective Therapies Group, Escalation Therapies Group; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions: Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells; Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer
Interventions: MSC-INFβ, Questionnaires; Genetic · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, Radiation Therapy, Recombinant Interferon Beta; Drug · Other · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta 1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Multiple Sclerosis Relapse
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Interferon Beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Betaseron (Interferon beta-1b, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 85
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Interferon-beta (IFN-beta); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 21
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more

Conditions: Multiple Sclerosis
Interventions: Rebif®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: Up to 18 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 31
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 8
States / cities: Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more

Search by objective public record fields.

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

BEYOND Pilot Study

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis